This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Agios (AGIO) Stock Might be a Great Pick
by Zacks Equity Research
Agios (AGIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Agios' (AGIO) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Agios' (AGIO) loss and revenues better estimates in Q1. The company's wholly owned leukemia drug Tibsovo sees a sequential rise in sales.
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 65.29% and 182.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for April 30th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios' IND for PKR Activator AG-946 Gets FDA Clearance
by Zacks Equity Research
The FDA passes Agios' (AGIO) investigational new drug application for its next-generation PKR activator, AG-946. The company plans to begin a phase I study on the same in mid-2020.
Why Is Agios Pharmaceuticals (AGIO) Down 28.7% Since Last Earnings Report?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios' (AGIO) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Agios (AGIO) rides high on earnings and revenue beat in the fourth quarter of 2019.
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte's Application for Pemigatinib Gets EMA's Validation
by Zacks Equity Research
The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.
What Makes Agios Pharmaceuticals (AGIO) a New Buy Stock
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Agios' (AGIO) leukemia drug Tibsovo for treating relapsed/refractory myelodysplastic syndrome in adult patients with a susceptible IDH1 mutation.
Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.
Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Although Agios (AGIO) betters loss estimates in Q3, its revenues lag the same. The company's wholly owned leukemia drug Tibsovo sees a rise in sales sequentially.
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 2.16% and -10.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study
by Zacks Equity Research
Agios' (AGIO) Tibsovo improves progression free survival and reduces risk of disease progression or death in a phase III study in previously treated patients with IDH1 mutant cholangiocarcinoma.
Agios Pharmaceuticals (AGIO) Down 11.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios Rides High on Tibsovo Sales Amid Acute Competition
by Zacks Equity Research
Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.
Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales
by Zacks Equity Research
Agios (AGIO) incurs wider-than-expected loss in Q2 while revenues beat estimates. The company's newly approved leukemia drug Tibsovo sees a rise in sales sequentially.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -8.09% and 6.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios (AGIO) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
Agios (AGIO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Agios Pharmaceuticals (AGIO) Down 8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study
by Zacks Equity Research
Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.